What's Next in PV podcast

E6: Safety Databases in Pharmacovigilance: Selection, Validation, and Migration

0:00
49:00
Retroceder 15 segundos
Avanzar 15 segundos

Every pharmacovigilance system runs on a safety database — the central engine where every ICSR is entered, processed, and reported. But choosing, validating, and maintaining that database is one of the most consequential infrastructure decisions a biotech will make, and one of the most common sources of inspection findings when it is done badly.

In Episode 6 of What's Next in PV, Tereza Korecka speaks with Jan Kolouch and Vojtech Kvita from NextPV Services about how to approach the safety database decision end to end:

  • What a safety database actually does inside the PV system, and when a company can function without one
  • How vendor choice depends on ICSR volume, functionality, region, and budget — not just brand name
  • Build vs. buy vs. outsource: control, cost, and who really owns your data in each model
  • What GAMP 5 and EU Annex 11 validation actually requires: URS, IQ/OQ/PQ, and change control
  • Practical setup steps: dictionaries, workflows, SOPs, and EudraVigilance gateway testing
  • What triggers a database migration, and why it is one of the most error-prone PV projects
  • Why due diligence, not the vendor's brand, determines whether the system holds up at inspection

This is a practical conversation for PV, QA, IT, and biotech leaders selecting, validating, or migrating a safety database.

Hosted by Tereza Korecka | Guests: Jan Kolouch and Vojtech Kvita, NextPV Services

(00:00) - Intro music and episode introduction(00:31) - Opening and guest greetings(00:41) - Today's topic: safety databases(00:58) - What a safety database does inside the PV system(02:16) - Do you actually need one? Volume, PSURs, and reporting obligations(03:26) - Overview question: which vendors do companies choose from(03:51) - Main selection factors: volume, functionality, region, and budget(07:45) - Large vs. small organizations: enhanced functionality vs. practicality(11:26) - Build, buy, or outsource: framing the decision(11:59) - The build option, database ownership, and vendor-managed models(16:46) - Why building your own database is rare in practice today(18:21) - GAMP validation: what the process actually looks like(19:00) - URS, FS, IQ/OQ/PQ, GAMP 5, EU Annex 11, and the EU AI Act(23:21) - Beyond validation: what companies trip up on at setup(23:52) - Database setup: dictionaries, workflows, SOPs, and EudraVigilance gateway testing(29:22) - Changing databases: what actually triggers a migration(29:46) - Migration scenarios: E2B exports, script migration, and data enrichment(34:27) - When migrations slip: deviations, mitigation, and inspections(36:54) - Closing advice for biotechs facing a database decision(37:34) - Operating model, timeline buffers, and post-launch monitoring(42:18) - Due diligence as the thread through the whole process(45:23) - Migration usually happens alongside the day job(46:20) - Why it helps to have an internal database point person(47:33) - Closing remarks


Keywords:
pharmacovigilance, safety database, Oracle Argus, ArisGlobal LSMV, Veeva Vault Safety, GAMP 5, EU Annex 11, database validation, database migration, EudraVigilance gateway, ICSR, PV system, biotech pharmacovigilance

Otros episodios de "What's Next in PV"